522 reports of this reaction
2.8% of all BETAMETHASONE DIPROPIONATE reports
#3 most reported adverse reaction
MACULAR DEGENERATION is the #3 most commonly reported adverse reaction for BETAMETHASONE DIPROPIONATE. There are 522 FDA adverse event reports linking BETAMETHASONE DIPROPIONATE to MACULAR DEGENERATION. This represents approximately 2.8% of all 18,714 adverse event reports for this drug.
Patients taking BETAMETHASONE DIPROPIONATE who experience macular degeneration should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MACULAR DEGENERATION is a less commonly reported adverse event for BETAMETHASONE DIPROPIONATE, but still significant enough to appear in the safety profile.
In addition to macular degeneration, the following adverse reactions have been reported for BETAMETHASONE DIPROPIONATE:
The following drugs have also been linked to macular degeneration in FDA adverse event reports:
MACULAR DEGENERATION has been reported as an adverse event in 522 FDA reports for BETAMETHASONE DIPROPIONATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
MACULAR DEGENERATION accounts for approximately 2.8% of all adverse event reports for BETAMETHASONE DIPROPIONATE, making it one of the most commonly reported side effect.
If you experience macular degeneration while taking BETAMETHASONE DIPROPIONATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.